12:00 AM
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

BAY 86-9766: Phase II data

An open-label, Asian Phase II trial in 65 evaluable patients with unresectable HCC showed that twice-daily 50 mg oral BAY 86-9766 plus sorafenib as first-line treatment produced a DCR of 43%, with 3 confirmed partial responses and 25 cases of stable disease for >=10 weeks. Median TTP was 4.1 months and OS data are not...

Read the full 252 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >